A brief history of oral peptides
Summary
The Substack article traces the history and challenges of delivering peptide drugs orally, highlighting the long-standing problem of GI digestion and very low bioavailability. It explains how SNAC enabled Novo Nordisk's oral semaglutide as a notable advance, compares it to other permeation enhancers, and discusses regulatory and ethical considerations surrounding the Hims oral semaglutide case.